19. Essener Peritonealdialyse-Gespräch – Wie kann die Prognose von PD-Patienten verbessert werden?

• Literatur

• 1 McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int 2009; 76: 371-375
• 2 Burton JO, Jeffreys HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914-920
• 3 Hothi DK, Rees L, Marek J et al. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 2009; 4: 790-797
• 4 Jefferies HJ, Virk B, Schiller B et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011; 6: 1326-1332
• 5 Jefferies HJ, Burton JO, McIntyre CW. Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability. Blood Purif 2011; 32: 63-68
• 6 McIntyre CW. Hemodynamic effects of peritoneal dialysis. Perit Dial Int 2011; 31: S73-S76
• 7 Bargman JM. The CANUSA study and the importance of residual kidney function in dialysis patients. Kidney Int 2010; 77: 931
• 8 van der Wal WM, Noordzij M, Dekker FW et al.; Netherlands Cooperative Study on the Adequacy of Dialysis Study Group (NECOSAD). Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 2011; 26: 2978-2983
• 9 Jansen MA, Korevaar JC, Dekker FW et al.; NECOSAD Study Group. Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 2001; 12: 157-163
• 10 Ma T, Ding G. Effects of residual renal function on left ventricle and analysis of related factors in patients with hemodialysis. Ren Fail 2013; 35: 198-203
• 11 Herget-Rosenthal S, Ostrowski Mvon, Kribben A. Definition and risk factors of rapidly declining residual renal function in peritoneal dialysis: an observational study. Kidney Blood Press Res 2012; 35: 233-241
• 12 Lui SL, Yung S, Yim A et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60: 966-975
• 13 Johnson DW, Brown FG, Clarke M et al.; balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant 2012; 27: 4445-4453
• 14 Kim S, Oh KH, Oh J et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36: 305-316
• 15 Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
• 16 Gokal R. Fluid management and cardiovascular outcome in peritoneal dialysis patients. Semin Dial 1999; 12: 126-132
• 17 Lameire N, Biesen Wvan. Importance of blood pressure and volume control in peritoneal dialysis patients. Perit Dial Int 2001; 21: 206-211